BridgeBio Oncology Therapeutics, Inc. Payments to Acquire Marketable Securities
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Payments to Acquire Marketable Securities of $319.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $7.54M, a 77.82% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $311.64M, a 1175.51% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $21.04M.
- BridgeBio Oncology Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $4.46M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $319.18M 10-Q · filed 2026-08-11 | $340.23M derived: sum of 3 quarters · filed 2026-08-11 | $344.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $311.64M 10-Q · filed 2026-05-12 | $332.69M derived: sum of 2 quarters · filed 2026-05-12 | $337.15M derived: sum of 3 quarters · filed 2026-05-12 | $371.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $21.04M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $25.51M derived: sum of 2 quarters · filed 2026-04-30 | $59.49M derived: sum of 3 quarters · filed 2026-08-11 | $83.92M POS AM · filed 2026-04-30 |
| 2025-09-30 | $4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $38.45M derived: sum of 2 quarters · filed 2026-08-11 | $62.88M 10-Q · filed 2025-11-12 | $62.88M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $33.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $58.42M 10-Q · filed 2026-08-11 | $58.42M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | $24.43M 10-Q · filed 2026-05-12 | $24.43M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $0.00 derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $154.43M POS AM · filed 2026-04-30 | ||
| 2024-09-30 | $154.43M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |